Abstract

The Animal Models and Pathology Core is established to provide essential animal and pathology resource components that comprehensively support research Projects utilizing animal models.
The Specific Aims of this Core are:
Specific Aim 1 - To maintain quality controlled breeding colonies for various mouse strains;
Specific Aim 2 - To develop novel strains of transgenic mice and maintain breeding colonies of mice that will be specifically utilized by individual Projects in the Program;
Specific Aim 3 - To generate mouse embryonic fibroblasts (MEFs) from various mice strains proposed in individual projects;
Specific Aim 4 - To provide animal pathology services for in vivo cancer models;
and Specific Aim 5 - To provide services for tumor tissue staining and characterization by IHC and TMA.

Public Health Relevance

The central objective of the Animal Models and Pathology Core is to provide the PPG investigators with the knowledge, resources, and ability to utilize animal models, pathological examination, and analyses in the execution of their research projects and their advancement to preclinical studies. The Core is an integral part of the research program with regard to examination of lipid metabolism and signaling mechanisms involved in the pathogenesis and treatment of solid tumors.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA203628-06
Application #
10114128
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2016-05-01
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
6
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29407

  Publications

Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800
Chatterjee, Shilpak; Chakraborty, Paramita; Daenthanasanmak, Anusara et al. (2018) Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res :
Schrecengost, Randy S; Green, Cecelia L; Zhuang, Yan et al. (2018) In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183. J Pharmacol Exp Ther 365:107-116
Ogretmen, Besim (2018) Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 18:33-50
Helke, Kristi; Angel, Peggi; Lu, Ping et al. (2018) Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. Sci Rep 8:1627
Chatterjee, Shilpak; Daenthanasanmak, Anusara; Chakraborty, Paramita et al. (2018) CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metab 27:85-100.e8
Scheffel, Matthew J; Helke, Kristi; Lu, Ping et al. (2017) Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis. Sci Rep 7:15552
Gencer, Salih; Oleinik, Natalia; Kim, Jisun et al. (2017) TGF-? receptor I/II trafficking and signaling at primary cilia are inhibited by ceramide to attenuate cell migration and tumor metastasis. Sci Signal 10:
Sofi, M Hanief; Heinrichs, Jessica; Dany, Mohammed et al. (2017) Ceramide synthesis regulates T cell activity and GVHD development. JCI Insight 2:
Britten, Carolyn D; Garrett-Mayer, Elizabeth; Chin, Steven H et al. (2017) A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 23:4642-4650

Showing the most recent 10 out of 13 publications